In the last trading session, 4.51 million shares of the CytomX Therapeutics Inc (NASDAQ:CTMX) were traded, and its beta was 1.15. Most recently the company’s share price was $0.96, and it changed around $0.16 or 19.85% from the last close, which brings the market valuation of the company to $76.99M. CTMX currently trades at a discount to its 52-week high of $5.06, offering almost -427.08% off that amount. The share price’s 52-week low was $0.40, which indicates that the current value has risen by an impressive 58.33% since then.
CytomX Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 2.00. If we narrow it down even further, the data shows that 0 out of 6 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 2 recommended CTMX as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight. CytomX Therapeutics Inc is expected to report earnings per share of 0.13 for the current quarter.
CytomX Therapeutics Inc (NASDAQ:CTMX) trade information
Instantly CTMX has showed a green trend with a performance of 19.85% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 1.0000 on recent trading dayincreased the stock’s daily price by 4.0%. The company’s shares are currently down -6.68% year-to-date, but still up 35.78% over the last five days. On the other hand, CytomX Therapeutics Inc (NASDAQ:CTMX) is 76.98% up in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $3.46, which translates to bulls needing to increase their stock price by 72.25% from its current value. Analyst projections state that CTMX is forecast to be at a low of $3.25 and a high of $3.68.
CytomX Therapeutics Inc (CTMX) estimates and forecasts
The year-over-year growth rate is expected to be -23.19%, down from the previous year.
Consensus estimates provided by 4 financial analysts predict the company will bring in an average of 35.42M in revenue for the current quarter. 4 analysts expect CytomX Therapeutics Inc to make 31.87M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 41.46M and 25.11M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -14.57%. Forecasts for the next quarter put sales growth at 26.91%.
CTMX Dividends
CytomX Therapeutics Inc’s next quarterly earnings report is expected to be released in June.
JANUS HENDERSON GROUP PLC, with 7.4245% or 6.3 million shares worth $7.72 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund were the top two Mutual Funds as of Dec 31, 2024 . The former held 2.46 shares worth $2.36 million, making up 3.05% of all outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund held roughly 981.49 shares worth around $0.94 million, which represents about 1.22% of the total shares outstanding.
